| Previous close | 0.0100 |
| Open | 0.0100 |
| Bid | 0.0000 |
| Ask | 0.0100 |
| Strike | 25.50 |
| Expiry date | 2024-05-03 |
| Day's range | 0.0100 - 0.0200 |
| Contract range | N/A |
| Volume | |
| Open interest | 8.48k |
- GuruFocus.com
OPKO Health Inc (OPK) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves Amid ...
Key developments include a major asset sale and a focus on pharmaceutical innovation, despite a challenging financial quarter.
- Reuters
UPDATE 2-Pfizer reports patient death in Duchenne gene therapy study
A young patient died due to cardiac arrest after receiving Pfizer's experimental gene therapy being tested in a mid-stage trial for a muscle-wasting disorder called Duchenne muscular dystrophy(DMD), the drugmaker told Reuters on Tuesday. "A fatal serious adverse event was reported as cardiac arrest for a participant in the Phase 2 DAYLIGHT study," a company spokesperson told Reuters in an emailed response. The trial is testing boys 2 to three years of age with DMD, a genetic muscle wasting disorder in which most patients lack the protein dystrophin which keeps muscles intact.
- Reuters
Pfizer reports patient death in Duchenne gene therapy study
A young boy died due to a cardiac arrest in a mid-stage trial that tested Pfizer's experimental gene therapy for a muscle-wasting disorder called Duchenne muscular dystrophy (DMD), the drugmaker told Reuters on Tuesday. "A fatal serious adverse event was reported as cardiac arrest for a participant in the Phase 2 DAYLIGHT study," a company spokesperson told Reuters in an emailed response. The trial tested boys 2 years to less than 4 years of age with DMD, a genetic muscle wasting disorder in which most patients lack the protein dystrophin which keeps muscles intact.
